tbuckley/cabot-search huggingface dataset:
Patient Quality of Life After Interpolated Flap Repair of Nasal Mohs Surgery Defects
Authors: Tess M. Lukowiak, Allison M. Perz, Surya A. Veerabagu, Michael P. Lee, Donald Neal, Leora Aizman, Christopher J. Miller, Nicholas Golda, John G. Albertini, Todd Holmes, Anna Bar, Justin Leitenberger, Ian A. Maher, Joseph F. Sobanko, David Chen, Sumaira Aasi, Adam Sutton, H. William Higgins, Thuzar M. Shin, Christine Weinberger, Adam Mattox, Ashley Wysong, Jeremy R. Etzkorn
Journal: JAMA Dermatology (2021)

Single-center studies have shown that patients report better skin cancer-specific quality of life (QOL) after Mohs micrographic surgery (MMS), but it is unclear whether this improved QOL applies to patients after MMS and complex reconstruction in cosmetically sensitive areas.To evaluate patient QOL after MMS and interpolation flap reconstruction for patients with nasal skin cancers.This multicenter prospective survey study used the Skin Cancer Index (SCI), a validated, 15-question QOL questionnaire administered at 4 time points: before MMS, 1 week after flap placement, 4 weeks after flap takedown, and 16 weeks after flap takedown. Patients age 18 years or older with a nasal skin cancer who presented for MMS and were anticipated to undergo 2-stage interpolated flap repair by a Mohs surgeon were recruited from August 9, 2018, to February 2, 2020, at 8 outpatient MMS locations across the United States, including both academic centers and private practices.Mean difference in overall SCI score before MMS vs 16 weeks after flap takedown.A total of 169 patients (92 men [54.4%]; mean [SD] age, 67.7 [11.4] years) were enrolled, with 147 patients (75 men [51.0%]; mean [SD] age, 67.8 [11.7] years) completing SCI surveys both before MMS and 16 weeks after flap takedown. Total SCI scores improved significantly 16 weeks after flap takedown compared with pre-MMS scores, increasing by a mean of 13% (increase of 7.11 points; 95% CI, 5.48-8.76; P < .001). All 3 SCI subscale scores (emotion, appearance, and social) improved significantly (emotion subscale, increase of 3.27 points; 95% CI, 2.35-4.18; P < .001; appearance subscale, increase of 1.65 points; 95% CI, 1.12-2.18; P < .001; and social subscale, increase of 2.10 points; 95% CI, 1.55-2.84; P < .001) 16 weeks after flap takedown compared with pre-MMS.Removal of a nasal skin cancer and repair of the resulting defect can be distressing for patients. However, this cohort study suggests that physicians referring patients for MMS can be reassured that their patient's QOL will improve on average after surgery, even when a complex reconstruction is required.
Follistatin‐controlled activin‐HNF4α‐coagulation factor axis in liver progenitor cells determines outcome of acute liver failure
Authors: Tao Lin, Shanshan Wang, Stefan Munker, Kyounghwa Jung, Ricardo U. Macías‐Rodríguez, Astrid Ruiz‐Margáin, Robert Schierwagen, Hui Liu, Chen Shao, Chunlei Fan, Rilu Feng, Xiaodong Yuan, Sai Wang, Franziska Wandrer, Christoph Meyer, Ralf Wimmer, Roman Liebe, Jens Kroll, Long Zhang, Tobias Schiergens, Peter ten Dijke, Andreas Teufel, Alexander Marx, Peter R. Mertens, Hua Wang, Matthias P.A. Ebert, Heike Bantel, Enrico N. De Toni, Jonel Trebicka, Steven Dooley, Donghun Shin, Huiguo Ding, Hong‐Lei Weng
Journal: Hepatology (2021)

In patients with acute liver failure (ALF) who suffer from massive hepatocyte loss, liver progenitor cells (LPCs) take over key hepatocyte functions, which ultimately determines survival. This study investigated how the expression of hepatocyte nuclear factor 4α (HNF4α), its regulators, and targets in LPCs determines clinical outcome of patients with ALF.Clinicopathological associations were scrutinized in 19 patients with ALF (9 recovered and 10 receiving liver transplantation). Regulatory mechanisms between follistatin, activin, HNF4α, and coagulation factor expression in LPC were investigated in vitro and in metronidazole-treated zebrafish. A prospective clinical study followed up 186 patients with cirrhosis for 80 months to observe the relevance of follistatin levels in prevalence and mortality of acute-on-chronic liver failure. Recovered patients with ALF robustly express HNF4α in either LPCs or remaining hepatocytes. As in hepatocytes, HNF4α controls the expression of coagulation factors by binding to their promoters in LPC. HNF4α expression in LPCs requires the forkhead box protein H1-Sma and Mad homolog 2/3/4 transcription factor complex, which is promoted by the TGF-β superfamily member activin. Activin signaling in LPCs is negatively regulated by follistatin, a hepatocyte-derived hormone controlled by insulin and glucagon. In contrast to patients requiring liver transplantation, recovered patients demonstrate a normal activin/follistatin ratio, robust abundance of the activin effectors phosphorylated Sma and Mad homolog 2 and HNF4α in LPCs, leading to significantly improved coagulation function. A follow-up study indicated that serum follistatin levels could predict the incidence and mortality of acute-on-chronic liver failure.These results highlight a crucial role of the follistatin-controlled activin-HNF4α-coagulation axis in determining the clinical outcome of massive hepatocyte loss-induced ALF. The effects of insulin and glucagon on follistatin suggest a key role of the systemic metabolic state in ALF.
Myoblast mechanotransduction and myotube morphology is dependent on BAG3 regulation of YAP and TAZ
Authors: K. Arda Günay, Jason S. Silver, Tze-Ling Chang, Olivia J. Bednarski, Kendra L. Bannister, Cameron J. Rogowski, Bradley B. Olwin, Kristi S. Anseth
Journal: Biomaterials (2021)
27737 The clinical spectrum of primary cutaneous CD4 + small/medium-sized pleomorphic T-cell lymphoproliferative disorder: An updated systematic literature review and case series
Authors: Philip Surmanowicz, Sean Doherty, Arunima Sivanand, Nikoo Parvinnejad, Jean Deschenes, Michelle Schneider, Robert Gniadecki
Journal: Journal of the American Academy of Dermatology (2021)
Publisher Correction: Autophagy promotes growth of tumors with high mutational burden by inhibiting a T-cell immune response
Authors: Laura Poillet-Perez, Daniel W. Sharp, Yang Yang, Saurabh V. Laddha, Maria Ibrahim, Praveen K. Bommareddy, Zhixian Sherrie Hu, Joshua Vieth, Michael Haas, Marcus W. Bosenberg, Joshua D. Rabinowitz, Jian Cao, Jun-Lin Guan, Shridar Ganesan, Chang S. Chan, Janice M. Mehnert, Edmund C. Lattime, Eileen White
Journal: Nature Cancer (2021)
25406 Comparison of biologic initiation and health care costs among patients with psoriasis receiving fixed-dose combination halobetasol-propionate 0.01%/tazarotene 0.045% (HP/TAZ) lotion vs calcipotriene 0.005%/ betamethasone dipropionate 0.064% (CAL/BD) foam
Authors: Leon Kircik, George Joseph, Patrick Gagnon-Sanschagrin, Brock Bumpass, Elizabeth Serra, Tina Lin, Abby Jacobson, Annie Guérin, Brad P. Glick
Journal: Journal of the American Academy of Dermatology (2021)
27506 Quality of life and pruritus over 52 weeks of apremilast treatment in biologic-naive patients with moderate plaque psoriasis: Results of a real-world, multicenter, prospective study in Greece (APRAISAL)
Authors: Dimitrios Ioannides, Eleftheria Tampouratzi, Dimitrios Rigopoulos, Alexandros Drosos, Evangelia Rovithi, Evangelia Papadavid, Marina Papageorgiou, Ioannis Bassukas, Efterpi Zafiriou, Pantelis Panagakis
Journal: Journal of the American Academy of Dermatology (2021)
The Effect of BabySeq on Pediatric and Genomic Research—More Than Baby Steps
Authors: Beth A. Tarini
Journal: JAMA Pediatrics (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Higher Enhancement Intrahepatic Nodules on the Hepatobiliary Phase of Gd-EOB-DTPA-Enhanced MRI as a Poor Responsive Marker of Anti-PD-1/PD-L1 Monotherapy for Unresectable Hepatocellular Carcinoma
Authors: Tomoko Aoki, Naoshi Nishida, Kazuomi Ueshima, Masahiro Morita, Hirokazu Chishina, Masahiro Takita, Satoru Hagiwara, Hiroshi Ida, Yasunori Minami, Akira Yamada, Keitaro Sofue, Masakatsu Tsurusaki, Masatoshi Kudo
Journal: Liver Cancer (2021)

Immune checkpoint inhibitors (ICIs) are promising agents for the treatment of hepatocellular carcinoma (HCC). However, the establishment of noninvasive measure that could predict the response to ICIs is challenging. This study aimed to evaluate tumor responses to ICIs using the hepatobiliary phase of gadolinium-ethoxybenzyl-diethylenetriamine (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI), which was shown to reflect Wnt/β-catenin activating mutation.A total of 68 intrahepatic HCC nodules from 18 patients with unresectable HCC and Child-Pugh class A liver function who received anti-programmed cell death 1 (PD-1)/programmed death-ligand 1 (PD-L1) monotherapy were enrolled in this study. All patients had viable intrahepatic lesions evaluable using the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI within the 6 months prior to the treatment. The relative enhancement ratio was calculated, and the time to nodular progression (TTnP) defined as 20% or more increase in each nodule was compared between higher or hypo-enhancement HCC nodules. Then, the progression-free survival (PFS) and objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) were compared between patients with and without HCC nodules with higher enhancement on hepatobiliary phase images.The median PFS was 2.7 (95% confidence interval [CI]: 1.4-4.0) months in patients with HCC nodules with higher enhancement (n = 8) and 5.8 (95% CI: 0.0-18.9) months in patients with hypointense HCC nodules (n = 10) (p = 0.007). The median TTnP of HCC nodules with higher enhancement (n = 23) was 1.97 (95% CI: 1.86-2.07) months and that of hypointense HCC nodules (n = 45) was not reached (p = 0.003). The ORR was 12.5% (1/8) versus 30.0% (3/10); the disease control rate was 37.5% (3/8) versus 70.0% (7/10), respectively, in patients with or without higher enhancement intrahepatic HCC nodules.The TTnP on HCC nodules with higher enhancement and the median PFS in patients who carried higher enhancement intrahepatic HCC nodules were significantly shorter than those in hypointense HCC nodules with anti-PD-1/PD-L1 monotherapy. The intensity of the nodule on the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI is a promising imaging biomarker for predicting unfavorable response with anti-PD-1/PD-L1 monotherapy in patients with HCC.
Receipt of Guideline-Concordant Care Does Not Explain Breast Cancer Mortality Disparities by Race in Metropolitan Atlanta
Authors: Lindsay J. Collin, Ming Yan, Renjian Jiang, Keerthi Gogineni, Preeti Subhedar, Kevin C. Ward, Jeffrey M. Switchenko, Joseph Lipscomb, Jasmine Miller-Kleinhenz, Mylin A. Torres, Jolinta Lin, Lauren E. McCullough
Journal: Journal of the National Comprehensive Cancer Network (2021)

Background: Racial disparities in breast cancer mortality in the United States are well documented. Non-Hispanic Black (NHB) women are more likely to die of their disease than their non-Hispanic White (NHW) counterparts. The disparity is most pronounced among women diagnosed with prognostically favorable tumors, which may result in part from variations in their receipt of guideline care. In this study, we sought to estimate the effect of guideline-concordant care (GCC) on prognosis, and to evaluate whether receipt of GCC modified racial disparities in breast cancer mortality. Patients and Methods: Using the Georgia Cancer Registry, we identified 2,784 NHB and 4,262 NHW women diagnosed with a stage I–III first primary breast cancer in the metropolitan Atlanta area, Georgia, between 2010 and 2014. Women were included if they received surgery and information on their breast tumor characteristics was available; all others were excluded. Receipt of recommended therapies (chemotherapy, radiotherapy, endocrine therapy, and anti-HER2 therapy) as indicated was considered GCC. We used Cox proportional hazards models to estimate the impact of receiving GCC on breast cancer mortality overall and by race, with multivariable adjusted hazard ratios (HRs). Results: We found that NHB and NHW women were almost equally likely to receive GCC (65% vs 63%, respectively). Failure to receive GCC was associated with an increase in the hazard of breast cancer mortality (HR, 1.74; 95% CI, 1.37–2.20). However, racial disparities in breast cancer mortality persisted despite whether GCC was received (HR GCC : 2.17 [95% CI, 1.61–2.92]; HR non-GCC : 1.81 [95% CI, 1.28–2.91] ). Conclusions: Although receipt of GCC is important for breast cancer outcomes, racial disparities in breast cancer mortality did not diminish with receipt of GCC; differences in mortality between Black and White patients persisted across the strata of GCC.
Covid-19 vaccines: GPs boost uptake by calling patients and teaming up with community groups
Authors: Elisabeth Mahase
Journal: BMJ (2021)

An east London general practice that called every one of its patients to discuss covid-19 vaccination and any related concerns has reported vaccination coverage rates above those in the surrounding area.

Farzana Hussain, a GP who runs a practice in Newham, where levels deprivation and poverty are high, singlehandedly started phoning patients within a few weeks of vaccinations beginning in January 2021, after noticing that only about half of her patients were taking up offers the vaccine, all of them white British.

Hussain used her days off to ring patients who had not yet had the vaccine to explain that they were eligible for it and to discuss any questions they might have, having been spurred on by reports that people from ethnic minorities were more likely to contract and die from covid-19.1 “These weren’t just 10 minute calls—they took a lot longer than the normal 10 minute appointments,” she told The BMJ .

Hussain said that she had built good relationships with many of her patients over the past 18 years while running the practice, especially the older and more vulnerable groups, and this helped with these conversations. She noted three major themes …
Case 25-2021: A 48-Year-Old Man with Fatigue and Leg Swelling
Authors: Amber B. Moore, Jonathan R. Wing, Reece J. Goiffon, Rebecca K. Leaf, Lana Tsao, Joseph Misdraji
Journal: New England Journal of Medicine (2021)

A 48-year-old man with alcohol use disorder was admitted because of weight gain, fatigue, and swelling in both legs. Sixteen months earlier, he had been hospitalized with mycoplasma pneumonia and, during that admission, had received a diagnosis of diabetes. A diagnostic test was performed.
Predictors of severe COVID-19 in a registry-based Swedish cohort of patients with COPD
Authors: Caroline Stridsman, Lowie E.G.W. Vanfleteren, Jon R. Konradsen, Sten Axelsson Fisk, Christophe Pedroletti, Yvonne Sjöö, Jörgen Syk, Therese Sterner, Anne Lindberg, Alf Tunsäter, Fredrik Nyberg, Ann Ekberg-Jansson, Johanna Karlsson Sundbaum
Journal: European Respiratory Journal (2021)

<b>Older age, male sex, low educational level, symptom burden, degree of obstruction, underweight, obesity, comorbidity and prior COPD inpatient or secondary care predict severe COVID-19 in patients with COPD</b>https://bit.ly/2VHZIEm
27599 Secukinumab administration by a 2 mL autoinjector demonstrates high efficacy with comparable safety and tolerability in adult patients with plaque psoriasis: 16-week results from MATURE
Authors: Bardur Sigurgeirsson, John Browning, Stephen Tyring, Jacek C. Szepietowski, Raquel Rivera-Díaz, Isaak Effendy, Gerard Bruin, Bertrand Paguet, Rong Fu, Isabelle Hampele, Manmath Patekar
Journal: Journal of the American Academy of Dermatology (2021)
Targeting Akt in cancer for precision therapy
Authors: Hui Hua, Hongying Zhang, Jingzhu Chen, Jiao Wang, Jieya Liu, Yangfu Jiang
Journal: Journal of Hematology & Oncology (2021)

Biomarkers-guided precision therapeutics has revolutionized the clinical development and administration of molecular-targeted anticancer agents. Tailored precision cancer therapy exhibits better response rate compared to unselective treatment. Protein kinases have critical roles in cell signaling, metabolism, proliferation, survival and migration. Aberrant activation of protein kinases is critical for tumor growth and progression. Hence, protein kinases are key targets for molecular targeted cancer therapy. The serine/threonine kinase Akt is frequently activated in various types of cancer. Activation of Akt promotes tumor progression and drug resistance. Since the first Akt inhibitor was reported in 2000, many Akt inhibitors have been developed and evaluated in either early or late stage of clinical trials, which take advantage of liquid biopsy and genomic or molecular profiling to realize personalized cancer therapy. Two inhibitors, capivasertib and ipatasertib, are being tested in phase III clinical trials for cancer therapy. Here, we highlight recent progress of Akt signaling pathway, review the up-to-date data from clinical studies of Akt inhibitors and discuss the potential biomarkers that may help personalized treatment of cancer with Akt inhibitors. In addition, we also discuss how Akt may confer the vulnerability of cancer cells to some kinds of anticancer agents.
The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes
Authors: Franklin H. Epstein, Valentin Fuster, Lina Badimon, Juan J. Badimon, James H. Chesebro
Journal: New England Journal of Medicine (1992)

IN the 19th century there were two major hypotheses to explain the pathogenesis of atherosclerosis: the "incrustation" hypothesis and the "lipid" hypothesis. The incrustation hypothesis of von Rokitansky,1 proposed in 1852 and modified by Duguid,2 suggested that intimal thickening resulted from fibrin deposition, with subsequent organization by fibroblasts and secondary lipid accumulation. The lipid hypothesis, proposed by Virchow3 in 1856, suggested that lipid in the arterial wall represented a transduction of blood lipid, which subsequently formed complexes with acid mucopolysaccharides; lipid accumulated in arterial walls because mechanisms of lipid deposition predominated over those of removal. The two hypotheses are now . . .
Reducing the health effects of hot weather and heat extremes: from personal cooling strategies to green cities
Authors: Ollie Jay, Anthony Capon, Peter Berry, Carolyn Broderick, Richard de Dear, George Havenith, Yasushi Honda, R Sari Kovats, Wei Ma, Arunima Malik, Nathan B Morris, Lars Nybo, Sonia I Seneviratne, Jennifer Vanos, Kristie L Ebi
Journal: The Lancet (2021)
Epigenetic modifiers synergize with immune-checkpoint blockade to enhance long-lasting antitumor efficacy
Authors: Marina Baretti, Mark Yarchoan
Journal: Journal of Clinical Investigation (2021)

Immune-checkpoint inhibitors are firmly established as pillars of cancer therapy, but only a minority of cancer patients currently benefit from these therapies, and therapeutic combinations that can enhance responses are urgently needed. Recently, histone deacetylases (HDACs) have emerged as potential targets for immune modulation, but critical questions remain about their mechanisms of action. In this issue of the JCI, Truong et al. assess whether the HDAC inhibitor entinostat can enhance anti–PD-1 treatment in a bladder cancer model. Entinostat promoted a T cell–inflamed phenotype and had substantial antitumor efficacy when used in combination with anti–PD-1 therapy. In addition, the authors showed that HDAC inhibition augmented tumor neoantigen presentation, resulting in the immune editing of tumor antigens. This study highlights a mechanism by which epigenetic modifier agents can synergize with immune-checkpoint blockade for enhanced and long-lasting antitumor activity.
Global guideline for the diagnosis and management of rare yeast infections: an initiative of the ECMM in cooperation with ISHAM and ASM
Authors: Sharon C-A Chen, John Perfect, Arnaldo L Colombo, Oliver A Cornely, Andreas H Groll, Danila Seidel, Kerstin Albus, Joao N de Almedia, Guillermo Garcia-Effron, Nicole Gilroy, Cornelia Lass-Flörl, Luis Ostrosky-Zeichner, Livio Pagano, Tamas Papp, Riina Rautemaa-Richardson, Jon Salmanton-García, Andrej Spec, Joerg Steinmann, Sevtap Arikan-Akdagli, Dorothee E Arenz, Rosanne Sprute, Luisa Duran-Graeff, Tomas Freiberger, Corrado Girmenia, Michelle Harris, Souha S Kanj, Maryam Roudbary, Olivier Lortholary, Joseph Meletiadis, Esther Segal, Felipe Francisco Tuon, Nathan Wiederhold, Tihana Bicanic, Jagdish Chander, Yee-Chun Chen, Po-Ren Hsueh, Margaret Ip, Patricia Munoz, Isabel Spriet, Elvis Temfack, Luis Thompson, Anna Maria Tortorano, Aristea Velegraki, Nelesh P Govender
Journal: The Lancet Infectious Diseases (2021)
Duodenoscope-associated infections: risks and countermeasures
Authors: Horst Neuhaus
Journal: Endoscopy (2021)

The exact number of endoscopic retrograde cholangiopancreatography (ERCP) procedures performed worldwide each year is not known; the estimate for the United States is up to 700 000 cases. The high case volume implies that even infrequent adverse events are clinically and economically relevant. These events include procedure-related infections, which occur in 0.5 %–3 % of cases [1]. Such infections are likely to be predominantly induced endogenously by translocation of oral or intestinal bacteria. The extent to which infections are caused by exogenous bacteria is not well known, as these are rarely considered in clinical practice. However, recent reports on outbreaks of duodenoscope-associated infections (DAIs) have led to an increased awareness of this device-related risk. Most of these outbreaks were caused by multidrug-resistant organisms (MDROs) transmitted through contaminated duodenoscopes as proven by molecular typing. Such organisms can cause serious and life-threatening infections.
Covid-19: Australian outbreak surges as New Zealand sees first domestic cases in six months
Authors: Owen Dyer
Journal: BMJ (2021)

Covid-19: Australian outbreak surges as New Zealand sees first domestic cases in six months Owen DyerNew Zealand and much of eastern Australia are in lockdown this week, but these two countries that once shared a covid bubble are on divergent trajectories as New Zealand scrambles to maintain a "zero covid" strategy that Australia has been forced to abandon.
25934 Bimekizumab efficacy for moderate to severe plaque psoriasis across patient subgroups: Pooled results from 3 multicenter, randomized, double-blinded phase 3 trials
Authors: Bruce Strober, Richard B. Warren, Peter Foley, Melinda Gooderham, Diamant Thaçi, Eva Cullen, Christopher Cioffi, Luke Peterson, Cynthia Madden, April Armstrong
Journal: Journal of the American Academy of Dermatology (2021)